Abstract
Anlotinib is a multi-target tyrosine kinase inhibitor developed independently in China. Its biological effects remain unclear in small-cell lung cancer (SCLC). The current study aimed to evaluate the effects of anlotinib in combination with irinotecan on H446 and H2227 SCLC cell lines and provide new treatment strategy for SCLC. Cell growth of two cell lines was inhibited by anlotinib, irinotecan and the combination in a dose-dependent manner. After 72 h incubation, the inhibition rate was greater in the combination group than all single drug group. A similar result was found when apoptosis was assessed after 12 h, but not after 6 h of treatment. Compared with single drug, combination drug suppressed the migration and invasion abilities in two cell lines; however, there was no difference between individual anlotinib or irinotecan. The colony formation rate was obviously lower in the combination group. Vascular endothelial growth factor receptor, fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor were expressed in two cell lines after treatment regardless single or combination, but FGFR was expressed more after combination treatment than anlotinib. The expression of phosphorylated (p) ERK was de...Continue Reading
References
May 9, 2001·Nucleic Acids Research·M W Pfaffl
Sep 19, 2002·Cancer·Pasi A JänneBruce E Johnson
May 18, 2005·Oncogene·Jiazhi SunSaïd M Sebti
Dec 20, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sai-Hong Ignatius OuJason A Zell
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gigi ChenDerick Lau
Sep 3, 2011·Molecular Cancer Therapeutics·Johannes TaegerSven A Lang
Feb 1, 2012·Expert Opinion on Emerging Drugs·Giulio MetroLucio Crinò
Dec 12, 2012·Journal of Internal Medicine·L Claesson-Welsh, M Welsh
May 23, 2013·Medicinal Research Reviews·Masaru Katoh, Hitoshi Nakagama
May 16, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anna M VargheseM Catherine Pietanza
Aug 30, 2014·Cytokine & Growth Factor Reviews·Stijn MoensPeter Carmeliet
Feb 6, 2015·The Journal of Clinical Investigation·Young Chul Kim, Kun-Liang Guan
May 24, 2015·The Oncologist·Yujie Zhao, Alex A Adjei
Jul 5, 2016·Cell Reports·Nadine S JahchanJulien Sage
Oct 8, 2016·Journal of Hematology & Oncology·Yongkun SunYihebali Chi
May 28, 2017·BMC Cancer·Yuki MisumiKoshiro Watanabe
Sep 10, 2017·Neoplasia : an International Journal for Oncology Research·Bryan OronskyCorey A Carter
Feb 16, 2018·Cancer Science·Chengying XieLiguang Lou
Feb 18, 2018·Gene·Binyan LinNa Lu
Apr 6, 2018·Acta Pharmacologica Sinica·Chen-Chun ZhongChuan Li
Aug 12, 2018·JAMA Oncology·Baohui HanYan Sun
Aug 28, 2018·Biochemical and Biophysical Research Communications·Chao HeYongqiang Hao
Sep 21, 2018·Journal of Hematology & Oncology·Guoshuang ShenJiuda Zhao